ライフサイエンスコーパス: anginal

1 Expected survival rates are good, as are the anginal and functional classifications, but there is a h

2 r =1-mm ST-segment depression, average daily anginal attack count and nitroglycerin usage.

3 e patients with coronary disease and > or =3 anginal attacks per week despite maximum recommended dos

4 among several compounds suggested to trigger anginal chest pain; however, the pH reached when a coron

5 The statistically significant reduction in anginal class and strong positive trends for remaining e

6 At six months, the anginal class improved by two or more classes in 49% of

7 th complete 12-month follow-up (n =27), mean anginal class improved from 3.5+/-0.5 pre-TMR to 2.8+/-0

8 Anginal complaints improved </=12 months after cell inje

9 d with improvements in myocardial perfusion, anginal complaints, and quality of life score </=12 mont

10 Ranolazine, an anti-anginal compound, has been shown to significantly improv

11 onship of ranolazine, a potentially new anti-anginal compound, on symptom-limited exercise duration.

12 hat is unknown, however, is whether any anti-anginal drugs (beta-blockers, long-acting nitrates, calc

13 Despite the use of anti-anginal drugs and/or percutaneous coronary interventions

14 e anti-ischemic therapy for their qualifying anginal episode and less likely to undergo invasive proc

15 Our analysis shows an improvement in anginal episodes (MD, -7.81; 95% confidence interval [CI

16 disease, were more likely than men to report anginal episodes and had more recorded ischemic periods

17 Anginal episodes and nitroglycerin use were recorded wit

18 Many patients with chronic angina experience anginal episodes despite revascularization and antiangin

19 e in increasing exercise testing or reducing anginal episodes or use of glyceryl trinitrate.

20 ary outcome was the average weekly number of anginal episodes over the last 6 weeks of the study.

21 The outcomes pooled were indices of angina (anginal episodes, Canadian Cardiovascular Society angina

22 d by improvements in surrogate end points of anginal episodes, use of antianginal medications, Canadi

23 s with troponin-positive acute chest pain or anginal equivalent and inconclusive diagnosis after clin

24 number of patients with refractory angina or anginal equivalent symptoms despite maximal medical ther

25 or = 50%), severe anginal symptoms (> or = 2 anginal events in preceding 24 h), use of aspirin in the

26 lectrocardiogram at presentation, at least 2 anginal events in prior 24 hours, use of aspirin in prio

27 everal dimensions of HRQOL including reduced anginal frequency and bodily pain as well as improved di

28 diovascular outcome, notably higher rates of anginal hospitalization, repeat catheterization, and gre

29 Anginal improvement occurred with a reduction in Canadia

30 Many anti-anginal medications also have benefit for reducing sympt

31 th angina-limited exercise discontinued anti-anginal medications and were randomized into a double-bl

32 onary artery disease were enrolled, and anti-anginal medications were stopped.

33 cular clinical relevance because chest pain, anginal or otherwise, has been shown to be a frequent bu

34 case history of an individual with possible anginal pain and asked how respondents would react to ex

35 xcept C7 and C8 segments, contributes to the anginal pain experienced in the chest and arm.

36 This innervation contributes to the anginal pain experienced in the neck and jaw.

37 neous thermal pain thresholds are related to anginal pain perception.

38 ld consist of a combined antithrombotic/anti-anginal regimen.

39 The impact of these findings on anginal relief and long-term outcome are not known.

40 ll p < or = 0.03) and a trend towards better anginal stability (p = 0.056).

41 The SAQ scores for exertional capacity, anginal stability and frequency, treatment satisfaction,

42 tients with Stable Coronary Artery Disease), anginal status was mapped each year in patients without

43 ciation between repeat revascularization and anginal status, according to the type of initial revascu

44 The patient-oriented composite endpoint, anginal status, and exercise testing, were not statistic

45 monly used despite the marked improvement in anginal status.

46 younger women presenting with stable angina-anginal symptom characterization may align with older wo

47 AD), known CAD (stenosis > or = 50%), severe anginal symptoms (> or = 2 anginal events in preceding 2

48 ss surgery persisted among those with severe anginal symptoms (31 percent of blacks underwent surgery

49 clinical presentation with exercise-related anginal symptoms (chest pain or dyspnea) with or without

50 sts because of their efficacy in controlling anginal symptoms (Dihydropyridine calcium channel blocke

51 Conversely, there was no association between anginal symptoms and CAD (63.2% [67 of 106 patients] vs

52 policy of PTCA was associated with improved anginal symptoms and exercise times.

53 Patients reported severe anginal symptoms and poor quality of life on the Seattle

54 s may explain how aortic stenosis can induce anginal symptoms and their prompt relief after PAVR.

55 evascularization especially if minimal or no anginal symptoms are present.

56 4, P<10-7) identified inducible ischemia and anginal symptoms as the most powerful predictors (83%, 6

57 Asians and Europeans interpret and act upon anginal symptoms differently.

58 en CPET parameters, myocardial ischaemia and anginal symptoms in patients with chronic coronary syndr

59 ith improvements in myocardial perfusion and anginal symptoms in patients with refractory angina pect

60 ter likelihood of seeking immediate care for anginal symptoms than Europeans; this finding indicates

61 n, mean age 66 +/- 10 years) with exertional anginal symptoms undergoing diagnostic angiography.

62 tatus and self-reported CVD among those with anginal symptoms was determined in multivariable-adjuste

63 By contrast, when anginal symptoms were relieved in five subjects by cessa

64 He developed typical anginal symptoms within 2 wk of discharge; however, coro

65 ar follow-up, 43 (72.9%) reported persistent anginal symptoms, 5 (8.5%) were taking an antiplatelet,

66 ly to be on dialysis (83% vs 44%), had fewer anginal symptoms, and were more likely to have coronary

67 ention (PCI) is usually performed to relieve anginal symptoms, but data are emerging to suggest that

68 icrovascular coronary spasm in patients with anginal symptoms, despite angiographically normal corona

69 eral trials have demonstrated a reduction in anginal symptoms, increases in exercise tolerance, and o

70 Among NHANES participants reporting anginal symptoms, participants with LEP were more likely

71 or IS could be attributed to improvements in anginal symptoms.

72 exercise thallium studies for evaluation of anginal symptoms.

73 ong 19 320 participants, 583 (3.0%) reported anginal symptoms.

74 y artery disease, the relief or reduction of anginal symptoms.

75 Rose questionnaire assessed the presence of anginal symptoms.

76 tective effects of preinfarction angina, the anginal "warm-up phenomenon," and studies performed on h